Bundesliga, kao i manje-više sve na Starom kontinentu, je suspendovana. Bar do početka aprila.
Ipak, ona je bila u centru pažnje i u vreme neposredno pre pandemije koronavirusa. Povod, verovatno se sećate, transparenti upućeni vlasniku Hofenhajma, Ditmaru Hopu.
Razlog napada na lokalnog biznismena je bio taj što ne poštuje “zlatno pravilo” nemačkog fudbala, odnosno da niko ne može da ima preko 50% udela u vlasništvu kluba.
Bayern Munich fans call Dietmar Hopp a “son of a bitch.”
Hansi Flick goes over immediately to tell the fans to remove the sign. #TSGFCB pic.twitter.com/a8t1bQJC33
— Davis VanOpdorp (@Davis_VanOpdorp) February 29, 2020
Ipak, spletom okolnosti, Hop koji ima punih 79 godina bi mogao biti heroj, ne samo Nemačke, već čitave planete.
Vlasnik Hofenhajma je glavni investitor i nemačke laboratorije CureVac. Laboratorija se bavi pronalaskom vakcina, a prethodni period su bili fokusirani na pronalazak leka protiv koronavirusa i postoje indicije da ima uspeha.
Florijan von der Melbe, suvlasnik CureVac-a, je u izjavi za Rojters potvrdio da se krenulo u testiranje vakcine na životinjama, do juna ili jula bi trebalo da krene i sa testiranjem na ljudima.
1/2 “Florian von der Muelbe, CureVac’s chief production officer and co-founder, told Reuters last week the company had started with a multitude of coronavirus vaccine candidates and was now selecting the two best to go into clinical trials… https://t.co/7J9EK2sdav
— Adrienn Kovacs (@AdriennSzkovacs) March 15, 2020
Koliko je stvar ozbiljna najbolje govori i to da je u celu priču ušao i predsednik SAD, Donald Tramp, koji pokušava da otkupi ekskluzivna prava na vakcinu, ali, navodno “samo za američko tržište”.
BREAKING: Trump is trying to gain EXCLUSIVE rights to a potential vaccine being developed by a German firm, CureVac. This was confirmed by a German government source, who said that Trump is trying to secure the vaccine, “but only for the United States.”https://t.co/fTpOrZz3rh
— Brian Tyler Cohen (@briantylercohen) March 15, 2020
CureVac focuses on the development of a mRNA-based coronavirus vaccine to protect people worldwide. We abstain from commenting on speculations and rejects allegations about offers for acquisition of our company or our technology.
To our press release: https://t.co/DQGWgdcUJc— CureVac (@CureVacAG) March 15, 2020
Najnovije sportske vesti čitajte i na našoj iOS i android aplikaciji – Objektiv.rs
Komentari (0)